Proton pump inhibitor use may increase dementia risk (2)

According to Pharmacy Today magazine, concerns are being raised about the risk of serious adverse effects due to the long-term use of proton pump inhibitors (PPIs) by geriatric patients. Although PPIs are among the most commonly used acid-suppressive therapies in the U.S., chronic PPI use has recently been associated with the risk of hip fracture, community-acquired pneumonia, Clostridium difficile infection, interstitial nephritis, hypomagnesemia, and myocardial infarction. In addition, data from two new German trials indicates that chronic PPI use by older adults may increase the risk of developing dementia:


Section GG requirements: How we’re helping our client communities comply (2)

LeadingAge recently provided an overview of the new Section GG: Functional Abilities and Goals, which is now part of the PPS 5-day assessment and the Part A PPS discharge assessment. The data in Section GG is needed to calculate a new CMS-mandated SNF-QRP quality measure that requires skilled-nursing providers to assess functional abilities at the beginning of a Part A stay and to set at least one discharge goal for an area of functional status listed in Section GG. CMS also now requires an assessment of usual function at the end of a Part A stay. Section GG is not required for any payer source other than original Medicare Part A.


The senior-living provider’s guide to Medicare open enrollment and 2016/2017 consumer mailings [Infographic]

It's that time of the year again! Along with the annual change of seasons from summer to fall comes Medicare open enrollment.

  • The Annual Election and Open Enrollment Periods will begin on October 15 and end on December 7, 2016.
  • Marketing by Medicare Part D plans will begin on October 1, 2016.
  • Medicare Part D plan changes will all take effect on January 1, 2017.


Symbria ESOP annual statements hitting home mailboxes soon

We're excited to announce that our ESOP administration partner, Principal, is mailing the first set of annual Symbria ESOP account statements this week! Your ESOP account statement will provide the first tangible results of our conversion to an employee-owned company and the beginning of what we expect to be a valuable retirement benefit for you.


Not to be missed



Regulatory round-up

In an effort to keep you up-to-date on the latest regulatory requirements, we've rounded up some important developments that are in the news this month. Read on to learn about a recent FDA ruling on the use of niacin and fenofibric acid with statins – and new quality measures for skilled-nursing providers.


FDA issues warnings about side effects of fluoroquinolones and olanzapine

By Symbria Rx Services Consultant Pharmacist Tom Crowley, PharmD, CGP

The FDA publishes Drug Safety Communications to share recently-observed risks of FDA-approved drugs. Two recent communications provided important new information about the potentially serious side effects that fluoroquinolones and olanzapine may cause.


Like us on Facebook: